Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis
- PMID: 35038311
- PMCID: PMC8859923
- DOI: 10.1530/EJE-21-0850
Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis
Abstract
Objective: Metformin is a first-line pharmacotherapy in the treatment of type 2 diabetes, a condition closely associated with non-alcoholic fatty liver disease (NAFLD). Although metformin promotes weight loss and improves insulin sensitivity, its effect on intrahepatic triglyceride (IHTG) remains unclear. We investigated the effect of metformin on IHTG, hepatic de novo lipogenesis (DNL), and fatty acid (FA) oxidation in vivo in humans.
Design and methods: Metabolic investigations, using stable-isotope tracers, were performed in ten insulin-resistant, overweight/obese human participants with NAFLD who were treatment naïve before and after 12 weeks of metformin treatment. The effect of metformin on markers of s.c. adipose tissue FA metabolism and function, along with the plasma metabolome, was investigated.
Results: Twelve weeks of treatment with metformin resulted in a significant reduction in body weight and improved insulin sensitivity, but IHTG content and FA oxidation remained unchanged. Metformin treatment was associated with a significant decrease in VLDL-triglyceride (TG) concentrations and a significant increase in the relative contribution of DNL-derived FAs to VLDL-TG. There were subtle and relatively few changes in s.c. adipose tissue FA metabolism and the plasma metabolome with metformin treatment.
Conclusions: We demonstrate the mechanisms of action of metformin whereby it improves insulin sensitivity and promotes weight loss, without improvement in IHTG; these observations are partly explained through increased hepatic DNL and a lack of change in FA oxidation.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8859923/bin/EJE-21-0850fig1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8859923/bin/EJE-21-0850fig2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8859923/bin/EJE-21-0850fig3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8859923/bin/EJE-21-0850fig4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8859923/bin/EJE-21-0850fig5.gif)
Similar articles
-
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.J Clin Invest. 2020 Mar 2;130(3):1453-1460. doi: 10.1172/JCI134165. J Clin Invest. 2020. PMID: 31805015 Free PMC article. Clinical Trial.
-
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.Gastroenterology. 2008 Feb;134(2):424-31. doi: 10.1053/j.gastro.2007.11.038. Epub 2007 Nov 28. Gastroenterology. 2008. PMID: 18242210 Free PMC article.
-
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.Am J Clin Nutr. 2015 Jan;101(1):34-43. doi: 10.3945/ajcn.114.092262. Epub 2014 Nov 19. Am J Clin Nutr. 2015. PMID: 25527748 Free PMC article. Clinical Trial.
-
Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?Diabetes Obes Metab. 2019 Apr;21(4):749-760. doi: 10.1111/dom.13592. Epub 2018 Dec 21. Diabetes Obes Metab. 2019. PMID: 30456918 Review.
-
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.J Gastroenterol. 2013 Apr;48(4):434-41. doi: 10.1007/s00535-013-0758-5. Epub 2013 Feb 9. J Gastroenterol. 2013. PMID: 23397118 Free PMC article. Review.
Cited by
-
Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.Lipids Health Dis. 2024 Apr 2;23(1):95. doi: 10.1186/s12944-024-02092-2. Lipids Health Dis. 2024. PMID: 38566209 Free PMC article. Review.
-
Mitochondrial complex I inhibition triggers NAD+-independent glucose oxidation via successive NADPH formation, "futile" fatty acid cycling, and FADH2 oxidation.Geroscience. 2024 Aug;46(4):3635-3658. doi: 10.1007/s11357-023-01059-y. Epub 2024 Jan 25. Geroscience. 2024. PMID: 38267672 Free PMC article.
-
Metformin Inefficiency to Lower Lipids in Vitamin B12 Deficient HepG2 Cells Is Alleviated via Adiponectin-AMPK Axis.Nutrients. 2023 Dec 8;15(24):5046. doi: 10.3390/nu15245046. Nutrients. 2023. PMID: 38140305 Free PMC article.
-
Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential.Pharmaceuticals (Basel). 2023 Dec 11;16(12):1717. doi: 10.3390/ph16121717. Pharmaceuticals (Basel). 2023. PMID: 38139843 Free PMC article.
-
Metabolite profiles of diabetes mellitus and response to intervention in anti-hyperglycemic drugs.Front Endocrinol (Lausanne). 2023 Oct 31;14:1237934. doi: 10.3389/fendo.2023.1237934. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027178 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous